

Possibility of Using the Interferon Gamma Release Level As a Dynamic Biomarker

Tomonori Hirashima^{1*}, Hidekazu Suzuki¹, Tomohiro Kanai^{1,4}, Hiroko Yoshida², Yoshitaka Tamura², Norio Okamoto¹, Toshio Tanaka³

¹Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588, Japan

²Department of Clinical Laboratory, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588, Japan

³Department of Allergy, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588, Japan

⁴Department of Respiratory Medicine, Osaka General Medical Center 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka 558-8558, Japan

Commentary

Received date: 04/05/2020

Accepted date: 15/05/2020

Published date: 22/05/2020

*For Correspondence

Tomonori Hirashima, Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino, Habikino City, Osaka 583-8588, Japan,

E-mail: dhirashimat@ra.opho.jp

Keywords: Interferon-gamma release; Immune checkpoint inhibitor; Biomarker; Lung cancer; Cytomegalovirus infection; Systemic lupus erythematosus

ABSTRACT

The potential of using interferon- γ (IFN- γ) release as a biomarker was examined in the previous study. Twenty-nine patients treated with immune checkpoint inhibitors were divided into three groups according to their IFN- γ release level in the positive control after enzyme-linked immunosorbent assay. The three groups showed clear differences in clinical outcomes. IGR can be a new dynamic biomarker to determine the immunological status of a patient at the pretreatment stage or any change in the state of their immunity during the treatment of various diseases.

COMMENTARY

Several studies^[1-3] have reported that the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis and interferon-gamma (IFN- γ) are important for acquiring cellular immunity to *Mycobacterium Tuberculosis* (TB pathogen). In the previous study^[4], we attempted to verify the hypothesis that there are changes in the IFN- γ release (IGR) after immune checkpoint inhibitor treatment (ICI-tx) and also examined the usefulness of IGR as a biomarker. IGR was measured using enzyme-linked immunosorbent assay [QuantiFERON[®]-TB Gold Plus (QFT-TB)]. Based on the IFN- γ levels in the positive control, identified by a response to phytohemagglutinin (PHA), 29 patients with non-small-cell lung cancer (NSCLC) enrolled in the our study were divided into three groups: Group-1 (n=8), consisting of patients with <10 IU/ml at pretreatment, Group-2 (n=12) which included patients who displayed a decrease in the IFN- γ level to <10 IU/ml during ICI-tx, and Group-3 (n=9) where the IFN- γ levels in patients did not decrease below 10 IU/ml even after treatment. Group-1 tended to have higher levels of both neutrophil-to-lymphocyte ratio and C-reactive protein, and lower levels of both body mass index and serum albumin, than the other groups. Group-1 may have a poor immunological status, including cancer-associated inflammation and malnutrition, as described in our previous study^[5]. Early progression and ICI-induced interstitial pneumonitis were frequently observed in Group-1 and Group-2, respectively. Group-3 exhibited more treatment cycles than the other groups. Subsequently, we concluded that IFN- γ levels could be a biomarker for ICI-Tx.

Huang et al.^[6] reported that a higher pre-treatment PHA-stimulated IFN- γ response (High-PHA) was associated with better survival among advanced NSCLC patients treated with chemotherapy. This result was similar to that of our recent study^[7], which

indicated High-PHA, which may reflect a better immunological status, was associated with better progression free survival. Yong et al. ^[8] reported that low IFN- γ response to PHA in the Quantiferon[®] Cytomegalovirus at the 3-month time-point following allogeneic hematopoietic stem cell transplantation was predictive of reduced 12-month overall survival, increased non-relapse mortality, and reduced survival in recipients with acute graft versus host disease (GVHD). This result was similar to our previous study ^[4] that the reduction of response to PHA after ICI-tx was correlated with both poor treatment outcomes and ICI-induced interstitial pneumonitis. In our recent study ^[7], we explained that common post-treatment reduction is observed in the following scenarios: 1) As a cytotoxic T-Cell (CTL) in GVHD recognizes a specific antigen in the recipients, it will display a low response to any non-specific stimulation from PHA; 2) ICI-tx would promote T-Cell to differentiate into a CTL that respond to specific antigen and, subsequently, may remove non-specific response for PHA. Therefore, we speculated that a decrease in the IFN- γ levels in patients with immune-related adverse events may resemble the loss of response for PHA in severe GVHD. Thomason et al. ^[9] suggested that elevated IGR in the negative control of the QFT-TB assay may offer a readily available tool in the form of a biomarker for assessing the disease activity in patients with systemic lupus erythematosus. Furthermore, in future, if cancer-antigen ^[10] in substitution for TB antigen could be used on QFT-TB, prediction of ICI-tx efficacy may become possible by improved QFT-TB.

Thus, IGR can be a dynamic biomarker to detect the immunological status at pretreatment or the change in the state of immunity during various diseases.

REFERENCES

1. Barber DL, et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. *J Immunol.* 2011; 186: 1598-1607.
2. Sakai S, et al. CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. *PLoSPathog.* 2016; 12: e1005667.
3. Tousif S, et al. T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. *PLoS One.* 2011; 6: e19864.
4. Hirashima T, et al. The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. *Anticancer Res.* 2019; 39: 6231-6240.
5. Shiroyama T, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. *Cancer Med.* 2018; 7: 13-20.
6. Huang HC, et al. The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer. *Lung Cancer.* 2018; 115: 64-70.
7. Kanai T, et al. Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors. *Anticancer Res.* 2020; 40: 2787-2793.
8. Yong MK, et al. Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. *Front Immunol.* 2017; 8: 1506.
9. Thomason JL, et al. An interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus. *Rheumatology (Oxford)*, 2020.
10. Ohue Y, et al. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. *J ThoracOncol.* 2019; 14: 2071-2083.